Holen Sie sich die Stockscreener-App
1.66
0.60%
-0.01
Vorhandelsmarkt:
1.65
-0.01
-0.60%
Schlusskurs vom Vortag:
$1.67
Offen:
$1.68
24-Stunden-Volumen:
480.56K
Relative Volume:
1.13
Marktkapitalisierung:
$42.01M
Einnahmen:
$160.43M
Nettoeinkommen (Verlust:
$-227.64M
KGV:
-0.0241
EPS:
-68.77
Netto-Cashflow:
$-170.79M
1W Leistung:
-0.60%
1M Leistung:
-41.96%
6M Leistung:
-68.74%
1J Leistung:
-85.08%
1-Tages-Spanne:
$1.65
$1.765
1-Wochen-Bereich:
$1.55
$1.765
52-Wochen-Spanne:
$1.55
$19.69
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Vergleichen Sie AGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
1.66 | 42.01M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Breakthrough Cancer Treatment Data: Agenus BOT/BAL Shows Promise Across Multiple Cancers - StockTitan
Agenus stock hits 52-week low at $1.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Agenus stock hits 52-week low at $1.64 amid sharp annual decline - Investing.com Australia
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation - Lelezard
93% of Doctors Say Current Colorectal Cancer Treatments Fall Short, New Study Shows - StockTitan
H.C. Wainwright maintains neutral on Agenus stock post-10-K filing - Investing.com Australia
AGENUS INC SEC 10-K Report - TradingView
Gilead Sciences : Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead - Marketscreener.com
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Equities Analysts Offer Predictions for Agenus Q1 Earnings - Defense World
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - Defense World
Agenus stock falls after revenue miss - MSN
Agenus (AGEN) Q4 2024 Earnings Call Transcript - AOL
Agenus stock hits 52-week low at $1.91 amid market challenges - Investing.com Australia
Earnings call transcript: Agenus sees stock jump in Q4 2024 By Investing.com - Investing.com Australia
Agenus Inc. Earnings Call: Mixed Sentiments and Strategic Focus - TipRanks
Agenus stock hits 52-week low at $1.91 amid market challenges By Investing.com - Investing.com South Africa
Agenus Inc. (NASDAQ:AGEN) Q4 2024 Earnings Call Transcript - MSN
Agenus’ Strategic Cost Reductions and CRC Focus Lead to Hold Rating - TipRanks
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Mo - GuruFocus.com
Agenus Inc. Reports Strategic Cost Reductions and BOT/BAL Progress - TipRanks
Agenus: Q4 Earnings Snapshot - mySA
Agenus stock falls as Q4 revenue drops sharply - Investing.com India
Agenus stock falls as Q4 revenue drops sharply By Investing.com - Investing.com South Africa
Earnings call transcript: Agenus sees stock jump in Q4 2024 - Investing.com India
Agenus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Agenus: Q4 Earnings Snapshot -March 11, 2025 at 07:44 am EDT - Marketscreener.com
Agenus to lower annual burn to about $50 mln by mid-2025 -March 11, 2025 at 07:40 am EDT - Marketscreener.com
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program - Business Wire
Earnings Scheduled For March 11, 2025 - Benzinga
Agenus Slashes Cash Burn by 50% While Advancing Promising Cancer Drug Program - StockTitan
Class Action Filed Against Agenus Inc. (AGEN) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Contrasting Agenus (NASDAQ:AGEN) and Cortexyme (NASDAQ:CRTX) - Defense World
Agenus (AGEN) Projected to Post Earnings on Tuesday - Defense World
Agenus Inc. to Host Earnings Call - ACCESS Newswire
Agenus stock touches 52-week low at $2.48 amid market challenges - Investing.com Australia
Agenus stock touches 52-week low at $2.48 amid market challenges By Investing.com - Investing.com South Africa
Agenus reports promising sarcoma study results - MSN
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.46%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):